drugset / Trial / NCT00800579

Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

NCT00800579 ↗

Phase 1 Completed 12 enrolled Gilead Sciences
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of escalating doses of GS-9411 in healthy male volunteers. GS-9411 is a sodium channel inhibitor, that may restore airway hydration and mucociliary clearance in the lung.

Timeline

Start
2008-11
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject GS-9411 Small molecule 0.6 mg Inhaled
Subject GS-9411 Small molecule 1.2 mg Inhaled
Subject GS-9411 Small molecule 2.4 mg Inhaled

Indications